BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Jiao Q, Bi L, Ren Y, Song S, Wang Q, Wang YS. Advances in studies of tyrosine kinase inhibitors and their acquired resistance. Mol Cancer 2018;17:36. [PMID: 29455664 DOI: 10.1186/s12943-018-0801-5] [Cited by in Crossref: 105] [Cited by in F6Publishing: 99] [Article Influence: 26.3] [Reference Citation Analysis]
Number Citing Articles
1 Chen M, Cao Y, Dong D, Zhang Z, Zhang Y, Chen J, Luo Y, Chen Q, Xiao X, Zhou J, Xie W, Li D, Xie S, Liu M. Regulation of mitotic spindle orientation by phosphorylation of end binding protein 1. Exp Cell Res 2019;384:111618. [PMID: 31505167 DOI: 10.1016/j.yexcr.2019.111618] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
2 Fang F, Yuan Q. Anlotinib inhibits the proliferation, migration and invasion, and induces apoptosis of breast cancer cells by downregulating TFAP2C. Oncol Lett 2022;23:46. [PMID: 34976158 DOI: 10.3892/ol.2021.13164] [Reference Citation Analysis]
3 Ma A, Biersack B, Goehringer N, Nitzsche B, Höpfner M. Novel Thienyl-Based Tyrosine Kinase Inhibitors for the Treatment of Hepatocellular Carcinoma. JPM 2022;12:738. [DOI: 10.3390/jpm12050738] [Reference Citation Analysis]
4 Huang XL, Khan MI, Wang J, Ali R, Ali SW, Zahra QU, Kazmi A, Lolai A, Huang YL, Hussain A, Bilal M, Li F, Qiu B. Role of receptor tyrosine kinases mediated signal transduction pathways in tumor growth and angiogenesis-New insight and futuristic vision. Int J Biol Macromol 2021;180:739-52. [PMID: 33737188 DOI: 10.1016/j.ijbiomac.2021.03.075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zhou X, Li TM, Luo JZ, Lan CL, Wei ZL, Fu TH, Liao XW, Zhu GZ, Ye XP, Peng T. CYP2C8 Suppress Proliferation, Migration, Invasion and Sorafenib Resistance of Hepatocellular Carcinoma via PI3K/Akt/p27kip1 Axis. J Hepatocell Carcinoma 2021;8:1323-38. [PMID: 34765572 DOI: 10.2147/JHC.S335425] [Reference Citation Analysis]
6 AlAsmari AF, Ali N, AlAsmari F, AlAnazi WA, AlShammari MA, Al-Harbi NO, Alhoshani A, As Sobeai HM, AlSwayyed M, AlAnazi MM, AlGhamdi NS. Liraglutide attenuates gefitinib-induced cardiotoxicity and promotes cardioprotection through the regulation of MAPK/NF-κB signaling pathways. Saudi Pharm J 2020;28:509-18. [PMID: 32273812 DOI: 10.1016/j.jsps.2020.03.002] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
7 Kurokawa R, Hagiwara A, Amemiya S, Gonoi W, Fujita N, Kurokawa M, Yamaguchi H, Nakai Y, Ota Y, Baba A, Kawahara T, Abe O. Imatinib-induced pancreatic hypertrophy in patients with gastrointestinal stromal tumor: Association with overall survival. Pancreatology 2021;21:246-52. [PMID: 33281059 DOI: 10.1016/j.pan.2020.11.014] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
8 Paranthaman S, Goravinahalli Shivananjegowda M, Mahadev M, Moin A, Hagalavadi Nanjappa S, Nanjaiyah N, Chidambaram SB, Gowda DV. Nanodelivery Systems Targeting Epidermal Growth Factor Receptors for Glioma Management. Pharmaceutics 2020;12:E1198. [PMID: 33321953 DOI: 10.3390/pharmaceutics12121198] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Zucchiatti P, Birarda G, Cerea A, Semrau MS, Hubarevich A, Storici P, De Angelis F, Toma A, Vaccari L. Binding of tyrosine kinase inhibitor to epidermal growth factor receptor: surface-enhanced infrared absorption microscopy reveals subtle protein secondary structure variations. Nanoscale 2021;13:7667-77. [PMID: 33928964 DOI: 10.1039/d0nr09200b] [Reference Citation Analysis]
10 Ilie MD, Lasolle H, Raverot G. Emerging and Novel Treatments for Pituitary Tumors. J Clin Med 2019;8:E1107. [PMID: 31349718 DOI: 10.3390/jcm8081107] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
11 Chauhan P, Mundekkad D, Mukherjee A, Chaudhary S, Umar A, Baskoutas S. Coconut Carbon Dots: Progressive Large-Scale Synthesis, Detailed Biological Activities and Smart Sensing Aptitudes towards Tyrosine. Nanomaterials (Basel) 2022;12:162. [PMID: 35010113 DOI: 10.3390/nano12010162] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 6.0] [Reference Citation Analysis]
12 Satheeshkumar R, Zhu R, Feng B, Huang C, Gao Y, Gao L, Shen C, Hou T, Xu L, Li J, Zhu Y, Zhou Y, Wang W. Synthesis and biological evaluation of heterocyclic bis-aryl amides as novel Src homology 2 domain containing protein tyrosine phosphatase-2 (SHP2) inhibitors. Bioorganic & Medicinal Chemistry Letters 2020;30:127170. [DOI: 10.1016/j.bmcl.2020.127170] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
13 Choi J, Topouza DG, Tarnouskaya A, Nesdoly S, Koti M, Duan QL. Gene networks and expression quantitative trait loci associated with adjuvant chemotherapy response in high-grade serous ovarian cancer. BMC Cancer 2020;20:413. [PMID: 32404140 DOI: 10.1186/s12885-020-06922-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
14 Pu C, Biyuan, Xu K, Zhao Y. Glycosylation and its research progress in endometrial cancer. Clin Transl Oncol 2022. [PMID: 35752750 DOI: 10.1007/s12094-022-02858-z] [Reference Citation Analysis]
15 Miyazawa Y, Rahman AB, Saga Y, Imafuku H, Hisamatsu Y, Aoki S. Catalytic Hydrolysis of Phosphate Monoester by Supramolecular Complexes Formed by the Self-Assembly of a Hydrophobic Bis(Zn2+-cyclen) Complex, Copper, and Barbital Units That Are Functionalized with Amino Acids in a Two-Phase Solvent System. Micromachines (Basel) 2019;10:E452. [PMID: 31277494 DOI: 10.3390/mi10070452] [Cited by in Crossref: 2] [Article Influence: 0.7] [Reference Citation Analysis]
16 Wium M, Ajayi-Smith AF, Paccez JD, Zerbini LF. The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications. Cancers (Basel) 2021;13:1521. [PMID: 33806258 DOI: 10.3390/cancers13071521] [Reference Citation Analysis]
17 Li G, Zhao M, Zhao L. Development and validation of an UPLC-MS/MS method for simultaneous determination of fifteen targeted anti-cancer drugs in human plasma and its application in therapeutic drug monitoring. Journal of Pharmaceutical and Biomedical Analysis 2021. [DOI: 10.1016/j.jpba.2021.114517] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Faria M, Domingues R, Bugalho MJ, Silva AL, Matos P. Analysis of NIS Plasma Membrane Interactors Discloses Key Regulation by a SRC/RAC1/PAK1/PIP5K/EZRIN Pathway with Potential Implications for Radioiodine Re-Sensitization Therapy in Thyroid Cancer. Cancers (Basel) 2021;13:5460. [PMID: 34771624 DOI: 10.3390/cancers13215460] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
19 Deligiorgi MV, Trafalis DT. The Clinical Relevance of Hypothyroidism in Patients with Solid Non-Thyroid Cancer: A Tantalizing Conundrum. J Clin Med 2022;11:3417. [PMID: 35743483 DOI: 10.3390/jcm11123417] [Reference Citation Analysis]
20 Sámano-Sánchez H, Gibson TJ. Mimicry of Short Linear Motifs by Bacterial Pathogens: A Drugging Opportunity. Trends Biochem Sci 2020;45:526-44. [PMID: 32413327 DOI: 10.1016/j.tibs.2020.03.003] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 3.5] [Reference Citation Analysis]
21 Bolcaen J, Nair S, Driver CHS, Boshomane TMG, Ebenhan T, Vandevoorde C. Novel Receptor Tyrosine Kinase Pathway Inhibitors for Targeted Radionuclide Therapy of Glioblastoma. Pharmaceuticals (Basel) 2021;14:626. [PMID: 34209513 DOI: 10.3390/ph14070626] [Reference Citation Analysis]
22 Kaehler M, Cascorbi I. Pharmacogenomics of Impaired Tyrosine Kinase Inhibitor Response: Lessons Learned From Chronic Myelogenous Leukemia. Front Pharmacol 2021;12:696960. [PMID: 34262462 DOI: 10.3389/fphar.2021.696960] [Reference Citation Analysis]
23 Rathi N, Maughan BL, Agarwal N, Swami U. Mini-Review: Cabozantinib in the Treatment of Advanced Renal Cell Carcinoma and Hepatocellular Carcinoma. Cancer Manag Res 2020;12:3741-9. [PMID: 32547210 DOI: 10.2147/CMAR.S202973] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
24 Alkamaly OM, Altwaijry N, Sabour R, Harras MF. Dual EGFR/VEGFR2 inhibitors and apoptosis inducers: Synthesis and antitumor activity of novel pyrazoline derivatives. Arch Pharm (Weinheim) 2021;354:e2000351. [PMID: 33252142 DOI: 10.1002/ardp.202000351] [Reference Citation Analysis]
25 Volodina YL, Dezhenkova LG, Tikhomirov AS, Tatarskiy VV, Kaluzhny DN, Moisenovich AM, Moisenovich MM, Isagulieva AK, Shtil AA, Tsvetkov VB, Shchekotikhin AE. New anthra[2,3-b]furancarboxamides: A role of positioning of the carboxamide moiety in antitumor properties. European Journal of Medicinal Chemistry 2019;165:31-45. [DOI: 10.1016/j.ejmech.2018.12.068] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 4.7] [Reference Citation Analysis]
26 Alkhezayem S, Wani TA, Wakil S, Aljuraysi A, Zargar S. Transcriptome analysis of neratinib treated HER2 positive cancer model vs untreated cancer unravels the molecular mechanism of action of neratinib. Saudi Pharm J 2020;28:963-70. [PMID: 32792841 DOI: 10.1016/j.jsps.2020.06.017] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
27 Wu MD, Moslehi JJ, Lindner JR. Arterial Thrombotic Complications of Tyrosine Kinase Inhibitors. Arterioscler Thromb Vasc Biol 2021;41:3-10. [PMID: 33275447 DOI: 10.1161/ATVBAHA.120.314694] [Reference Citation Analysis]
28 Worm DJ, Els‐heindl S, Beck‐sickinger AG. Targeting of peptide‐binding receptors on cancer cells with peptide‐drug conjugates. Peptide Science 2020;112. [DOI: 10.1002/pep2.24171] [Cited by in Crossref: 9] [Cited by in F6Publishing: 2] [Article Influence: 4.5] [Reference Citation Analysis]
29 Sarmento-Ribeiro AB, Scorilas A, Gonçalves AC, Efferth T, Trougakos IP. The emergence of drug resistance to targeted cancer therapies: Clinical evidence. Drug Resist Updat 2019;47:100646. [PMID: 31733611 DOI: 10.1016/j.drup.2019.100646] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 7.0] [Reference Citation Analysis]
30 Qi L, Zhang Y, Song F, Han Y, Ding Y. A newly identified small molecular compound acts as a protein kinase inhibitor to suppress metastasis of colorectal cancer. Bioorg Chem 2021;107:104625. [PMID: 33454506 DOI: 10.1016/j.bioorg.2021.104625] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
31 Moslehi M, Namdar F, Esmaeilifallah M, Hejazi SH, Sokhanvari F, Siadat AH, Hosseini SM, Iraji F. Evaluation of Different Concentrations of Imatinib on the Viability of Leishmania major: An In Vitro Study. Adv Biomed Res 2019;8:61. [PMID: 31737578 DOI: 10.4103/abr.abr_58_19] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
32 Neganova ME, Aleksandrova YR, Sukocheva OA, Klochkov SG. Benefits and limitations of nanomedicine treatment of brain cancers and age-dependent neurodegenerative disorders. Semin Cancer Biol 2022:S1044-579X(22)00155-9. [PMID: 35779712 DOI: 10.1016/j.semcancer.2022.06.011] [Reference Citation Analysis]
33 Silva VR, Neves SP, Santos LS, Dias RB, Bezerra DP. Challenges and Therapeutic Opportunities of Autophagy in Cancer Therapy. Cancers (Basel) 2020;12:E3461. [PMID: 33233671 DOI: 10.3390/cancers12113461] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 4.5] [Reference Citation Analysis]
34 Ilie MD, Vasiljevic A, Raverot G, Bertolino P. The Microenvironment of Pituitary Tumors-Biological and Therapeutic Implications. Cancers (Basel) 2019;11:E1605. [PMID: 31640258 DOI: 10.3390/cancers11101605] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
35 Chang Y, Roy S, Pan Z. Store-Operated Calcium Channels as Drug Target in Gastroesophageal Cancers. Front Pharmacol 2021;12:668730. [PMID: 34012400 DOI: 10.3389/fphar.2021.668730] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
36 Gaillard D, Barlow LA. A Mechanistic Overview of Taste Bud Maintenance and Impairment in Cancer Therapies. Chem Senses 2021;46:bjab011. [PMID: 33693542 DOI: 10.1093/chemse/bjab011] [Reference Citation Analysis]
37 Song W, Hu L, Ma Z, Yang L, Li J. Importance of Tyrosine Phosphorylation in Hormone-Regulated Plant Growth and Development. Int J Mol Sci 2022;23:6603. [PMID: 35743047 DOI: 10.3390/ijms23126603] [Reference Citation Analysis]
38 Secombe KR, Van Sebille YZA, Mayo BJ, Coller JK, Gibson RJ, Bowen JM. Diarrhea Induced by Small Molecule Tyrosine Kinase Inhibitors Compared With Chemotherapy: Potential Role of the Microbiome. Integr Cancer Ther 2020;19:1534735420928493. [PMID: 32493068 DOI: 10.1177/1534735420928493] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
39 Elakad O, Häupl B, Labitzky V, Yao S, Küffer S, von Hammerstein-Equord A, Danner BC, Jücker M, Urlaub H, Lange T, Ströbel P, Oellerich T, Bohnenberger H. Activation of CD44/PAK1/AKT signaling promotes resistance to FGFR1 inhibition in squamous-cell lung cancer. NPJ Precis Oncol 2022;6:52. [PMID: 35853934 DOI: 10.1038/s41698-022-00296-2] [Reference Citation Analysis]
40 Sherbiny FF, Bayoumi AH, El-Morsy AM, Sobhy M, Hagras M. Design, Synthesis, biological Evaluation, and molecular docking studies of novel Pyrazolo[3,4-d]Pyrimidine derivative scaffolds as potent EGFR inhibitors and cell apoptosis inducers. Bioorg Chem 2021;116:105325. [PMID: 34507234 DOI: 10.1016/j.bioorg.2021.105325] [Reference Citation Analysis]
41 Mukwaya A, Jensen L, Lagali N. Relapse of pathological angiogenesis: functional role of the basement membrane and potential treatment strategies. Exp Mol Med 2021;53:189-201. [PMID: 33589713 DOI: 10.1038/s12276-021-00566-2] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
42 Yung Y, Lee E, Chu HT, Yip PK, Gill H. Targeting Abnormal Hematopoietic Stem Cells in Chronic Myeloid Leukemia and Philadelphia Chromosome-Negative Classical Myeloproliferative Neoplasms. Int J Mol Sci 2021;22:E659. [PMID: 33440869 DOI: 10.3390/ijms22020659] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
43 Rodríguez-Hernández MA, de la Cruz-Ojeda P, López-Grueso MJ, Navarro-Villarán E, Requejo-Aguilar R, Castejón-Vega B, Negrete M, Gallego P, Vega-Ochoa Á, Victor VM, Cordero MD, Del Campo JA, Bárcena JA, Padilla CA, Muntané J. Integrated molecular signaling involving mitochondrial dysfunction and alteration of cell metabolism induced by tyrosine kinase inhibitors in cancer. Redox Biol 2020;36:101510. [PMID: 32593127 DOI: 10.1016/j.redox.2020.101510] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
44 Chhikara BS, Ashraf S, Mozaffari S, St Jeans N, Mandal D, Tiwari RK, Ul-Haq Z, Parang K. Phenylpyrazalopyrimidines as Tyrosine Kinase Inhibitors: Synthesis, Antiproliferative Activity, and Molecular Simulations. Molecules 2020;25:E2135. [PMID: 32370213 DOI: 10.3390/molecules25092135] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
45 Singh S, Utreja D, Kumar V. Pyrrolo[2,1-f][1,2,4]triazine: a promising fused heterocycle to target kinases in cancer therapy. Med Chem Res 2021;:1-25. [PMID: 34803342 DOI: 10.1007/s00044-021-02819-1] [Reference Citation Analysis]
46 You KS, Yi YW, Cho J, Park JS, Seong YS. Potentiating Therapeutic Effects of Epidermal Growth Factor Receptor Inhibition in Triple-Negative Breast Cancer. Pharmaceuticals (Basel) 2021;14:589. [PMID: 34207383 DOI: 10.3390/ph14060589] [Reference Citation Analysis]
47 Liu X, Zhan Y, Xu W, Liu X, Geng Y, Liu L, Da J, Wang J, Zhang X, Jin H, Liu Z, Guo S, Zhang B, Li Y. Prognostic and immunological role of Fam20C in pan-cancer. Biosci Rep 2021;41:BSR20201920. [PMID: 33306121 DOI: 10.1042/BSR20201920] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
48 Sudhesh Dev S, Zainal Abidin SA, Farghadani R, Othman I, Naidu R. Receptor Tyrosine Kinases and Their Signaling Pathways as Therapeutic Targets of Curcumin in Cancer. Front Pharmacol 2021;12:772510. [PMID: 34867402 DOI: 10.3389/fphar.2021.772510] [Reference Citation Analysis]
49 Deligiorgi MV, Trafalis DT. The continuum of care of anticancer treatment-induced hypothyroidism in patients with solid non thyroid tumors: time for an intimate collaboration between oncologists and endocrinologists. Expert Rev Clin Pharmacol 2022. [PMID: 35757870 DOI: 10.1080/17512433.2022.2093714] [Reference Citation Analysis]
50 Fan Y, Xue H, Zheng H. Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook. JHC 2022;Volume 9:233-63. [DOI: 10.2147/jhc.s358082] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
51 Sharma M, Prasher P. C2-functionalized imidazo[1,2-a]pyridine: Synthesis and medicinal relevance. Synthetic Communications. [DOI: 10.1080/00397911.2022.2079091] [Reference Citation Analysis]
52 Raverot G, Ilie MD, Lasolle H, Amodru V, Trouillas J, Castinetti F, Brue T. Aggressive pituitary tumours and pituitary carcinomas. Nat Rev Endocrinol 2021;17:671-84. [PMID: 34493834 DOI: 10.1038/s41574-021-00550-w] [Cited by in Crossref: 15] [Cited by in F6Publishing: 8] [Article Influence: 15.0] [Reference Citation Analysis]
53 Mao L, Sun G, Zhao J, Xu G, Yuan M, Li YM. Design, synthesis and antitumor activity of icotinib derivatives. Bioorg Chem 2020;105:104421. [PMID: 33181408 DOI: 10.1016/j.bioorg.2020.104421] [Cited by in Crossref: 2] [Article Influence: 1.0] [Reference Citation Analysis]
54 Grześk G, Woźniak-Wiśniewska A, Błażejewski J, Górny B, Wołowiec Ł, Rogowicz D, Nowaczyk A. The Interactions of Nintedanib and Oral Anticoagulants-Molecular Mechanisms and Clinical Implications. Int J Mol Sci 2020;22:E282. [PMID: 33396592 DOI: 10.3390/ijms22010282] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
55 Bunev AS, Khochenkov DA, Khochenkova YA, Machkova YS, Varakina EV, Gasanov RE, Troshina MA, Avdyakova OS. Synthesis and anticancer activity of novel 2-alkylthio-4-amino-5-(thiazol-2-YL)pyrimidines. Synthetic Communications 2021;51:2521-7. [DOI: 10.1080/00397911.2021.1939383] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
56 Nakhjavani M, Smith E, Yeo K, Palethorpe HM, Tomita Y, Price TJ, Townsend AR, Hardingham JE. Anti-Angiogenic Properties of Ginsenoside Rg3 Epimers: In Vitro Assessment of Single and Combination Treatments. Cancers (Basel) 2021;13:2223. [PMID: 34066403 DOI: 10.3390/cancers13092223] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
57 Li R, Zhou S, Li Y, Shen X, Wang Z, Chen B. Comparative Methylome Analysis Reveals Perturbation of Host Epigenome in Chestnut Blight Fungus by a Hypovirus. Front Microbiol 2018;9:1026. [PMID: 29875746 DOI: 10.3389/fmicb.2018.01026] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
58 Jian W, Wei CM, Guan JH, Mo CH, Xu YT, Zheng WB, Li L, Gui C. Association between serum HER2/ErbB2 levels and coronary artery disease: a case-control study. J Transl Med 2020;18:124. [PMID: 32160892 DOI: 10.1186/s12967-020-02292-1] [Reference Citation Analysis]
59 Manica M, Oskooei A, Born J, Subramanian V, Sáez-rodríguez J, Rodríguez Martínez M. Toward Explainable Anticancer Compound Sensitivity Prediction via Multimodal Attention-Based Convolutional Encoders. Mol Pharmaceutics 2019;16:4797-806. [DOI: 10.1021/acs.molpharmaceut.9b00520] [Cited by in Crossref: 35] [Cited by in F6Publishing: 26] [Article Influence: 11.7] [Reference Citation Analysis]
60 Morales ML, Arenas A, Ortiz-Ruiz A, Leivas A, Rapado I, Rodríguez-García A, Castro N, Zagorac I, Quintela-Fandino M, Gómez-López G, Gallardo M, Ayala R, Linares M, Martínez-López J. MEK inhibition enhances the response to tyrosine kinase inhibitors in acute myeloid leukemia. Sci Rep 2019;9:18630. [PMID: 31819100 DOI: 10.1038/s41598-019-54901-9] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.7] [Reference Citation Analysis]
61 Onmaz DE, Abusoglu S, Unlu A, Basturk A, Dagli M, Bagci M, Tok O, Abusoglu G. Determination of serum imatinib and its' metabolite in patients chronic myeloid leukemia. Clin Chim Acta 2019;497:120-4. [PMID: 31351054 DOI: 10.1016/j.cca.2019.07.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
62 Sivaganesh V, Sivaganesh V, Scanlon C, Iskander A, Maher S, Lê T, Peethambaran B. Protein Tyrosine Phosphatases: Mechanisms in Cancer. Int J Mol Sci 2021;22:12865. [PMID: 34884670 DOI: 10.3390/ijms222312865] [Reference Citation Analysis]
63 Doycheva I, Thuluvath PJ. Systemic Therapy for Advanced Hepatocellular Carcinoma: An Update of a Rapidly Evolving Field. J Clin Exp Hepatol. 2019;9:588-596. [PMID: 31695249 DOI: 10.1016/j.jceh.2019.07.012] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
64 Mao J, Zhu K, Long Z, Zhang H, Xiao B, Xi W, Wang Y, Huang J, Liu J, Shi X, Jiang H, Lu T, Wen Y, Zhang N, Meng Q, Zhou H, Ruan Z, Wang J, Luo C, Xi X. Targeting the RT loop of Src SH3 in Platelets Prevents Thrombosis without Compromising Hemostasis. Adv Sci (Weinh) 2022;9:e2103228. [PMID: 35023301 DOI: 10.1002/advs.202103228] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
65 Argenziano M, Tortora C, Pota E, Di Paola A, Di Martino M, Di Leva C, Di Pinto D, Rossi F. Osteosarcoma in Children: Not Only Chemotherapy. Pharmaceuticals (Basel) 2021;14:923. [PMID: 34577623 DOI: 10.3390/ph14090923] [Reference Citation Analysis]
66 Khochenkov DA, Khochenkova YA, Machkova YS, Gasanov RE, Stepanova EV, Bunev AS. Synthesis and cytotoxic activity of novel 4-amino-5-cyano-2-sulfonylpyrimidines. Mendeleev Communications 2020;30:604-6. [DOI: 10.1016/j.mencom.2020.09.017] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
67 Aldeghi M, Gapsys V, de Groot BL. Predicting Kinase Inhibitor Resistance: Physics-Based and Data-Driven Approaches. ACS Cent Sci 2019;5:1468-74. [PMID: 31482130 DOI: 10.1021/acscentsci.9b00590] [Cited by in Crossref: 21] [Cited by in F6Publishing: 15] [Article Influence: 7.0] [Reference Citation Analysis]
68 Abduelkarem AR, Anbar HS, Zaraei SO, Alfar AA, Al-Zoubi OS, Abdelkarem EG, El-Gamal MI. Diarylamides in anticancer drug discovery: A review of pre-clinical and clinical investigations. Eur J Med Chem 2020;188:112029. [PMID: 31923860 DOI: 10.1016/j.ejmech.2019.112029] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
69 Jin J, Wu Y, Chen J, Shen Y, Zhang L, Zhang H, Chen L, Yuan H, Chen H, Zhang W, Luan X. The peptide PROTAC modality: a novel strategy for targeted protein ubiquitination. Theranostics 2020;10:10141-53. [PMID: 32929339 DOI: 10.7150/thno.46985] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
70 Mahmoud S, Samaha D, Mohamed MS, Abou Taleb NA, Elsawy MA, Nagamatsu T, Ali HI. Design, Synthesis, Antitumor Activity and Molecular Docking Study of Novel 5-Deazaalloxazine Analogs. Molecules 2020;25:E2518. [PMID: 32481639 DOI: 10.3390/molecules25112518] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
71 Almajali B, Al-Jamal HAN, Taib WRW, Ismail I, Johan MF, Doolaanea AA, Ibrahim WN. Thymoquinone, as a Novel Therapeutic Candidate of Cancers. Pharmaceuticals (Basel) 2021;14:369. [PMID: 33923474 DOI: 10.3390/ph14040369] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
72 Liang J, Wang S, Zhang G, He B, Bie Q, Zhang B. A New Antitumor Direction: Tumor-Specific Endothelial Cells. Front Oncol 2021;11:756334. [PMID: 34988011 DOI: 10.3389/fonc.2021.756334] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
73 Kudo-Saito C, Ozaki Y, Imazeki H, Hayashi H, Masuda J, Ozawa H, Ogiwara Y. Targeting Oncoimmune Drivers of Cancer Metastasis. Cancers (Basel) 2021;13:554. [PMID: 33535613 DOI: 10.3390/cancers13030554] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 4.0] [Reference Citation Analysis]
74 Ciaffaglione V, Consoli V, Intagliata S, Marrazzo A, Romeo G, Pittalà V, Greish K, Vanella L, Floresta G, Rescifina A, Salerno L, Sorrenti V. Novel Tyrosine Kinase Inhibitors to Target Chronic Myeloid Leukemia. Molecules 2022;27:3220. [PMID: 35630697 DOI: 10.3390/molecules27103220] [Reference Citation Analysis]
75 Malczewska M, Kośmider K, Bednarz K, Ostapińska K, Lejman M, Zawitkowska J. Recent Advances in Treatment Options for Childhood Acute Lymphoblastic Leukemia. Cancers 2022;14:2021. [DOI: 10.3390/cancers14082021] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
76 Noel J, Suzukawa K, Chavez E, Pak K, Wasserman SI, Kurabi A, Ryan AF. A kinase inhibitor screen identifies signaling pathways regulating mucosal growth during otitis media. PLoS One 2020;15:e0235634. [PMID: 32760078 DOI: 10.1371/journal.pone.0235634] [Reference Citation Analysis]
77 Ciftci HI, Bayrak N, Yıldırım H, Yıldız M, Radwan MO, Otsuka M, Fujita M, Tuyun AF. Discovery and structure–activity relationship of plastoquinone analogs as anticancer agents against chronic myelogenous leukemia cells. Arch Pharm Chem Life Sci 2019;352:1900170. [DOI: 10.1002/ardp.201900170] [Cited by in Crossref: 14] [Cited by in F6Publishing: 8] [Article Influence: 4.7] [Reference Citation Analysis]
78 Liu Y, Wang C, Li J, Zhu J, Zhao C, Xu H. Novel Regulatory Factors and Small-Molecule Inhibitors of FGFR4 in Cancer. Front Pharmacol 2021;12:633453. [PMID: 33981224 DOI: 10.3389/fphar.2021.633453] [Reference Citation Analysis]
79 Darwish IA, Darwish HW, Khalil NY, Sayed AYA. Experimental and Computational Evaluation of Chloranilic Acid as an Universal Chromogenic Reagent for the Development of a Novel 96-Microwell Spectrophotometric Assay for Tyrosine Kinase Inhibitors. Molecules 2021;26:744. [PMID: 33572664 DOI: 10.3390/molecules26030744] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
80 Mohammadi N, Bahmaei M, Sharif AM. Highly sensitive CuZnO-Fe3O4/rGO modified glassy carbon electrode for the electrochemical determination of acetaminophen, tyrosine and codeine in human blood plasma and urine. Journal of Electroanalytical Chemistry 2021;902:115768. [DOI: 10.1016/j.jelechem.2021.115768] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
81 Spitaleri A, Zia SR, Di Micco P, Al-Lazikani B, Soler MA, Rocchia W. Tuning Local Hydration Enables a Deeper Understanding of Protein-Ligand Binding: The PP1-Src Kinase Case. J Phys Chem Lett 2021;12:49-58. [PMID: 33300337 DOI: 10.1021/acs.jpclett.0c03075] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
82 Bhattacharya S, Goyal A, Kaur P, Singh R, Kalra S. Anticancer Drug-induced Thyroid Dysfunction. Eur Endocrinol 2020;16:32-9. [PMID: 32595767 DOI: 10.17925/EE.2020.16.1.32] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
83 Torres-Martinez Z, Delgado Y, Ferrer-Acosta Y, Suarez-Arroyo IJ, Joaquín-Ovalle FM, Delinois LJ, Griebenow K. Key genes and drug delivery systems to improve the efficiency of chemotherapy. Cancer Drug Resist 2021;4:163-91. [PMID: 34142021 DOI: 10.20517/cdr.2020.64] [Reference Citation Analysis]
84 Seo HY, Lee SH, Lee JH, Lee JH, Jang BK, Kim MK. Kahweol Induces Apoptosis in Hepatocellular Carcinoma Cells by Inhibiting the Src/mTOR/STAT3 Signaling Pathway. Int J Mol Sci 2021;22:10509. [PMID: 34638852 DOI: 10.3390/ijms221910509] [Reference Citation Analysis]
85 Shahare HV, Talele GS. Designing of benzothiazole derivatives as promising EGFR tyrosine kinase inhibitors: a pharmacoinformatics study. Journal of Biomolecular Structure and Dynamics 2020;38:1365-74. [DOI: 10.1080/07391102.2019.1604264] [Cited by in Crossref: 4] [Cited by in F6Publishing: 1] [Article Influence: 1.3] [Reference Citation Analysis]
86 Mihajlovic M, Ivkovic B, Jancic-stojanovic B, Zeljkovic A, Spasojevic-kalimanovska V, Kotur-stevuljevic J, Vujanovic D. Modulation of oxidative stress/antioxidative defence in human serum treated by four different tyrosine kinase inhibitors. Anti-Cancer Drugs 2020;31:942-9. [DOI: 10.1097/cad.0000000000000924] [Cited by in Crossref: 3] [Article Influence: 1.5] [Reference Citation Analysis]
87 Borgo C, Ruzzene M. Role of protein kinase CK2 in antitumor drug resistance. J Exp Clin Cancer Res 2019;38:287. [PMID: 31277672 DOI: 10.1186/s13046-019-1292-y] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 10.0] [Reference Citation Analysis]
88 Li Q, Su R, Bao X, Cao K, Du Y, Wang N, Wang J, Xing F, Yan F, Huang K, Feng S. Glycyrrhetinic acid nanoparticles combined with ferrotherapy for improved cancer immunotherapy. Acta Biomater 2022;144:109-20. [PMID: 35314366 DOI: 10.1016/j.actbio.2022.03.030] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
89 Dai B, Xiao Z, Zhu G, Mao B, Huang H, Guan F, Lin Z, Peng W, Liang X, Zhang B, Hu Z. WD Repeat Domain 5 Promotes Invasion, Metastasis and Tumor Growth in Glioma Through Up-Regulated Zinc Finger E-Box Binding Homeobox 1 Expression. Cancer Manag Res 2020;12:3223-35. [PMID: 32440219 DOI: 10.2147/CMAR.S237582] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
90 Chaudhari B, Patel H, Thakar S, Ahmad I, Bansode D. Optimizing the Sunitinib for cardio-toxicity and thyro-toxicity by scaffold hopping approach. In Silico Pharmacol 2022;10:10. [PMID: 35791431 DOI: 10.1007/s40203-022-00125-1] [Reference Citation Analysis]
91 Huang L, Jiang S, Shi Y. Tyrosine kinase inhibitors for solid tumors in the past 20 years (2001-2020). J Hematol Oncol 2020;13:143. [PMID: 33109256 DOI: 10.1186/s13045-020-00977-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 22] [Article Influence: 10.5] [Reference Citation Analysis]
92 Grillo E, Corsini M, Ravelli C, di Somma M, Zammataro L, Monti E, Presta M, Mitola S. A novel variant of VEGFR2 identified by a pan-cancer screening of recurrent somatic mutations in the catalytic domain of tyrosine kinase receptors enhances tumor growth and metastasis. Cancer Lett 2021;496:84-92. [PMID: 33035615 DOI: 10.1016/j.canlet.2020.09.027] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
93 Hermawati E, Ellita SD, Juliawaty LD, Hakim EH, Syah YM, Ishikawa H. Epoxyquinophomopsins A and B from endophytic fungus Phomopsis sp. and their activity against tyrosine kinase. J Nat Med 2021;75:217-22. [PMID: 33030695 DOI: 10.1007/s11418-020-01454-1] [Reference Citation Analysis]
94 Singh A, Raza A, Amin S, Damodaran C, Sharma AK. Recent Advances in the Chemistry and Therapeutic Evaluation of Naturally Occurring and Synthetic Withanolides. Molecules 2022;27:886. [PMID: 35164150 DOI: 10.3390/molecules27030886] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
95 Choi G, Kim D, Oh J. AI-Based Drug Discovery of TKIs Targeting L858R/T790M/C797S-Mutant EGFR in Non-small Cell Lung Cancer. Front Pharmacol 2021;12:660313. [PMID: 34393769 DOI: 10.3389/fphar.2021.660313] [Reference Citation Analysis]
96 Aubert L, Petit A, Bertrand Y, Ray-Lunven AF, Angoso M, Pluchart C, Millot F, Saultier P, Cheikh N, Pellier I, Plantaz D, Sirvent A, Thouvenin-Doublet S, Valduga J, Plat G, Rialland F, Henry C, Esvan M, Gandemer V. Therapeutic approach and outcome of children with Philadelphia chromosome-positive acute lymphoblastic leukemia at first relapse in the era of tyrosine kinase inhibitors: An SFCE retrospective study. Pediatr Blood Cancer 2022;69:e29441. [PMID: 34854546 DOI: 10.1002/pbc.29441] [Reference Citation Analysis]
97 Yin Z, Zou Y, Wang D, Huang X, Xiong S, Cao L, Zhang Y, Sun Y, Zhang N. Regulation of the Tec family of non-receptor tyrosine kinases in cardiovascular disease. Cell Death Discov 2022;8:119. [PMID: 35296647 DOI: 10.1038/s41420-022-00927-4] [Reference Citation Analysis]
98 Wang S, Zhou D, Xu Z, Song J, Qian X, Lv X, Luan J. Anti-tumor Drug Targets Analysis: Current Insight and Future Prospect. Curr Drug Targets 2019;20:1180-202. [PMID: 30947670 DOI: 10.2174/1389450120666190402145325] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
99 Darwish IA, Khalil NY, Darwish HW, Alzoman NZ, Al-Hossaini AM. Spectrophotometric and computational investigations of charge transfer complexes of chloranilic acid with tyrosine kinase inhibitors and application to development of novel universal 96-microwell assay for their determination in pharmaceutical formulations. Spectrochim Acta A Mol Biomol Spectrosc 2021;252:119482. [PMID: 33571740 DOI: 10.1016/j.saa.2021.119482] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
100 Tian Z, Niu X, Yao W. Receptor Tyrosine Kinases in Osteosarcoma Treatment: Which Is the Key Target? Front Oncol 2020;10:1642. [PMID: 32984034 DOI: 10.3389/fonc.2020.01642] [Cited by in Crossref: 13] [Cited by in F6Publishing: 9] [Article Influence: 6.5] [Reference Citation Analysis]
101 Özenver N, Kadioglu O, Fu Y, Efferth T. Kinome-Wide Profiling Identifies Human WNK3 as a Target of Cajanin Stilbene Acid from Cajanus cajan (L.) Millsp. Int J Mol Sci 2022;23:1506. [PMID: 35163434 DOI: 10.3390/ijms23031506] [Reference Citation Analysis]
102 Santana-Garrido Á, Reyes-Goya C, André H, Aramburu Ó, Mate A, Vázquez CM. Sunitinib-induced oxidative imbalance and retinotoxic effects in rats. Life Sci 2020;257:118072. [PMID: 32659367 DOI: 10.1016/j.lfs.2020.118072] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
103 Kaczmarska A, Śliwa P, Lejman M, Zawitkowska J. The Use of Inhibitors of Tyrosine Kinase in Paediatric Haemato-Oncology-When and Why? Int J Mol Sci 2021;22:12089. [PMID: 34769519 DOI: 10.3390/ijms222112089] [Reference Citation Analysis]
104 Martin ME, Reaves DK, Jeffcoat B, Enders JR, Costantini LM, Yeyeodu ST, Botta D, Kavanagh TJ, Fleming JM. Silver nanoparticles alter epithelial basement membrane integrity, cell adhesion molecule expression, and TGF-β1 secretion. Nanomedicine 2019;21:102070. [PMID: 31351238 DOI: 10.1016/j.nano.2019.102070] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
105 Szumilak M, Wiktorowska-Owczarek A, Stanczak A. Hybrid Drugs-A Strategy for Overcoming Anticancer Drug Resistance? Molecules 2021;26:2601. [PMID: 33946916 DOI: 10.3390/molecules26092601] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
106 Wang L, Li Y, Lyu Y, Wen H, Feng C. Association between copy-number alteration of +20q, -14q and -18p and cross-sensitivity to tyrosine kinase inhibitors in clear-cell renal cell carcinoma. Cancer Cell Int 2020;20:482. [PMID: 33041663 DOI: 10.1186/s12935-020-01585-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
107 Zinger A, Baudo G, Naoi T, Giordano F, Lenna S, Massaro M, Ewing A, Kim HR, Tasciotti E, Yustein JT, Taraballi F. Reproducible and Characterized Method for Ponatinib Encapsulation into Biomimetic Lipid Nanoparticles as a Platform for Multi-Tyrosine Kinase-Targeted Therapy. ACS Appl Bio Mater 2020;3:6737-45. [DOI: 10.1021/acsabm.0c00685] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
108 Negi P, Cheke RS, Patil VM. Recent advances in pharmacological diversification of Src family kinase inhibitors. Egypt J Med Hum Genet 2021;22. [DOI: 10.1186/s43042-021-00172-x] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
109 Smidova V, Michalek P, Goliasova Z, Eckschlager T, Hodek P, Adam V, Heger Z. Nanomedicine of tyrosine kinase inhibitors. Theranostics 2021;11:1546-67. [PMID: 33408767 DOI: 10.7150/thno.48662] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
110 Lafitte M, Lecointre C, Roche S. Roles of exosomes in metastatic colorectal cancer. Am J Physiol Cell Physiol 2019;317:C869-80. [PMID: 31291143 DOI: 10.1152/ajpcell.00218.2019] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
111 Tapia L, Solozabal N, Solà J, Pérez Y, Miller WT, Alfonso I. Modulation of Src Kinase Activity by Selective Substrate Recognition with Pseudopeptidic Cages. Chemistry 2021;27:9542-9. [PMID: 33904620 DOI: 10.1002/chem.202100990] [Reference Citation Analysis]
112 Fontana F, Limonta P. The multifaceted roles of mitochondria at the crossroads of cell life and death in cancer. Free Radic Biol Med 2021;176:203-21. [PMID: 34597798 DOI: 10.1016/j.freeradbiomed.2021.09.024] [Reference Citation Analysis]
113 Zhang DX, Vu LT, Ismail NN, Le MTN, Grimson A. Landscape of extracellular vesicles in the tumour microenvironment: Interactions with stromal cells and with non-cell components, and impacts on metabolic reprogramming, horizontal transfer of neoplastic traits, and the emergence of therapeutic resistance. Semin Cancer Biol 2021:S1044-579X(21)00013-4. [PMID: 33545339 DOI: 10.1016/j.semcancer.2021.01.007] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
114 Jacobs CF, Eldering E, Kater AP. Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19. Blood Adv 2021;5:913-25. [PMID: 33560402 DOI: 10.1182/bloodadvances.2020003768] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
115 Reyes-Goya C, Santana-Garrido Á, Soto-Astacio E, Aramburu Ó, Zambrano S, Mate A, Vázquez CM. Mechanism of Vascular Toxicity in Rats Subjected to Treatment with a Tyrosine Kinase Inhibitor. Toxics 2020;8:E49. [PMID: 32698382 DOI: 10.3390/toxics8030049] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
116 Augoff K, Hryniewicz-Jankowska A, Tabola R. Invadopodia: clearing the way for cancer cell invasion. Ann Transl Med 2020;8:902. [PMID: 32793746 DOI: 10.21037/atm.2020.02.157] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
117 Li E, Huang X, Zhang G, Liang T. Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy. J Exp Clin Cancer Res 2021;40:279. [PMID: 34479614 DOI: 10.1186/s13046-021-02055-w] [Reference Citation Analysis]
118 Stazi G, Fioravanti R, Mai A, Mattevi A, Valente S. Histone deacetylases as an epigenetic pillar for the development of hybrid inhibitors in cancer. Current Opinion in Chemical Biology 2019;50:89-100. [DOI: 10.1016/j.cbpa.2019.03.002] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 5.0] [Reference Citation Analysis]
119 Bueno MLP, Roversi FM. Tyrosine kinase inhibitor resistance: a case report on chronic myeloid leukemia and Gilbert's syndrome. AME Case Rep 2021;5:1. [PMID: 33634241 DOI: 10.21037/acr-20-107] [Reference Citation Analysis]
120 Ryan TD, Nagarajan R, Godown J. Pediatric Cardio-Oncology: Development of Cancer Treatment-Related Cardiotoxicity and the Therapeutic Approach to Affected Patients. Curr Treat Options Oncol 2019;20:56. [PMID: 31129800 DOI: 10.1007/s11864-019-0658-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
121 Kim K, Khang D. Past, Present, and Future of Anticancer Nanomedicine. Int J Nanomedicine 2020;15:5719-43. [PMID: 32821098 DOI: 10.2147/IJN.S254774] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
122 Shawky AM, Abourehab MA, Abdalla AN, Gouda AM. Optimization of pyrrolizine-based Schiff bases with 4-thiazolidinone motif: Design, synthesis and investigation of cytotoxicity and anti-inflammatory potency. European Journal of Medicinal Chemistry 2020;185:111780. [DOI: 10.1016/j.ejmech.2019.111780] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 7.0] [Reference Citation Analysis]
123 Kowalska M, Nowaczyk J, Fijałkowski Ł, Nowaczyk A. Paroxetine-Overview of the Molecular Mechanisms of Action. Int J Mol Sci 2021;22:1662. [PMID: 33562229 DOI: 10.3390/ijms22041662] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
124 Moukengue B, Lallier M, Marchandet L, Baud’huin M, Verrecchia F, Ory B, Lamoureux F. Origin and Therapies of Osteosarcoma. Cancers 2022;14:3503. [DOI: 10.3390/cancers14143503] [Reference Citation Analysis]
125 Oliveira A, Moura S, Pimentel L, Neto J, Dantas R, Silva-Jr F, Bastos M, Boechat N. New Imatinib Derivatives with Antiproliferative Activity against A549 and K562 Cancer Cells. Molecules 2022;27:750. [PMID: 35164014 DOI: 10.3390/molecules27030750] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
126 Al-otaibi JS, Mary YS, Thomas R, Narayana B. Theoretical Studies into the Spectral Characteristics, Biological Activity, and Photovoltaic Cell Efficiency of Four New Polycyclic Aromatic Chalcones. Polycyclic Aromatic Compounds. [DOI: 10.1080/10406638.2020.1747097] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
127 Li X, Tang J, Mao Y. Incidence and risk factors of drug-induced liver injury. Liver Int 2022. [PMID: 35353431 DOI: 10.1111/liv.15262] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
128 Kawauchi D, Takahashi M, Satomi K, Yamamuro S, Kobayashi T, Uchida E, Honda-Kitahara M, Narita Y, Iwadate Y, Ichimura K, Tomiyama A. The ALK inhibitors, alectinib and ceritinib, induce ALK-independent and STAT3-dependent glioblastoma cell death. Cancer Sci 2021;112:2442-53. [PMID: 33728771 DOI: 10.1111/cas.14885] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
129 Niu M, Yi M, Li N, Wu K, Wu K. Advances of Targeted Therapy for Hepatocellular Carcinoma. Front Oncol 2021;11:719896. [PMID: 34381735 DOI: 10.3389/fonc.2021.719896] [Reference Citation Analysis]
130 Li Y, Qian Y, Lou X, Hu Z, Hu Y, Zeng M, Liu Z. LuxS in Lactobacillus plantarum SS-128 Improves the Texture of Refrigerated Litopenaeus vannamei: Mechanism Exploration Using a Proteomics Approach. Front Microbiol 2022;13:892788. [PMID: 35711745 DOI: 10.3389/fmicb.2022.892788] [Reference Citation Analysis]
131 Benedetti F, Curreli S, Gallo RC, Zella D. Exogenous bacterial DnaK increases protein kinases activity in human cancer cell lines. J Transl Med 2021;19:60. [PMID: 33563293 DOI: 10.1186/s12967-021-02734-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
132 Liang X, Yang Q, Wu P, He C, Yin L, Xu F, Yin Z, Yue G, Zou Y, Li L, Song X, Lv C, Zhang W, Jing B. The synthesis review of the approved tyrosine kinase inhibitors for anticancer therapy in 2015-2020. Bioorg Chem 2021;113:105011. [PMID: 34091289 DOI: 10.1016/j.bioorg.2021.105011] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
133 Malale K, Fu J, Qiu L, Zhan K, Gan X, Mei Z. Hypoxia-Induced Aquaporin-3 Changes Hepatocellular Carcinoma Cell Sensitivity to Sorafenib by Activating the PI3K/Akt Signaling Pathway. Cancer Manag Res 2020;12:4321-33. [PMID: 32606928 DOI: 10.2147/CMAR.S243918] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
134 Jin W. The Role of Tyrosine Kinases as a Critical Prognostic Parameter and Its Targeted Therapies in Ewing Sarcoma. Front Cell Dev Biol 2020;8:613. [PMID: 32754598 DOI: 10.3389/fcell.2020.00613] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
135 Murugan AK, Liu R, Xing M. Identification and characterization of two novel oncogenic mTOR mutations. Oncogene 2019;38:5211-26. [PMID: 30918329 DOI: 10.1038/s41388-019-0787-5] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 4.0] [Reference Citation Analysis]
136 Tasker NR, Rastelli EJ, Burnett JC, Sharlow ER, Lazo JS, Wipf P. Tapping the therapeutic potential of protein tyrosine phosphatase 4A with small molecule inhibitors. Bioorg Med Chem Lett 2019;29:2008-15. [PMID: 31307888 DOI: 10.1016/j.bmcl.2019.06.048] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
137 Sobierajska P, Serwotka-Suszczak A, Szymanski D, Marycz K, Wiglusz RJ. Nanohydroxyapatite-Mediated Imatinib Delivery for Specific Anticancer Applications. Molecules 2020;25:E4602. [PMID: 33050306 DOI: 10.3390/molecules25204602] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
138 Wilson RB, Archid R, Reymond MA. Reprogramming of Mesothelial-Mesenchymal Transition in Chronic Peritoneal Diseases by Estrogen Receptor Modulation and TGF-β1 Inhibition. Int J Mol Sci 2020;21:E4158. [PMID: 32532126 DOI: 10.3390/ijms21114158] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
139 Waitman K, Parise-Filho R. New kinase and HDAC hybrid inhibitors: recent advances and perspectives. Future Med Chem 2022. [PMID: 35543381 DOI: 10.4155/fmc-2021-0276] [Reference Citation Analysis]
140 Mojtahedi H, Yazdanpanah N, Rezaei N. Chronic myeloid leukemia stem cells: targeting therapeutic implications. Stem Cell Res Ther 2021;12. [DOI: 10.1186/s13287-021-02659-1] [Reference Citation Analysis]
141 Metibemu DS, Akinloye OA, Akamo AJ, Ojo DA, Okeowo OT, Omotuyi IO. Exploring receptor tyrosine kinases-inhibitors in Cancer treatments. Egypt J Med Hum Genet 2019;20. [DOI: 10.1186/s43042-019-0035-0] [Cited by in Crossref: 10] [Cited by in F6Publishing: 4] [Article Influence: 3.3] [Reference Citation Analysis]
142 Ryan TD, Nagarajan R, Godown J. Cardiovascular Toxicities in Pediatric Cancer Survivors. Cardiol Clin. 2019;37:533-544. [PMID: 31587793 DOI: 10.1016/j.ccl.2019.07.002] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 4.5] [Reference Citation Analysis]